Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by CancerSlayer


V.TLT

RE:RE:FDA Approval for TLD1433 pdt almost certain IMHO

Kingpin68 wrote: Eog, what do you make of the wording here : 'Of the...

January 27, 2023

V.TLT

RE:RE:RE:Excellent news! Out first official exposure to ASCO world

StevenBirch wrote: That's what stuck out to me, previously they went to...

January 25, 2023

V.TLT

RE:RE:RE:Pfizer or Roche as jv partners for the NMIBC

thadeush wrote: I know nothing, but it seems pretty clear that TLD1433 is...

January 24, 2023

V.TLT

RE:RE:RE:RE:RE:RE:somethings gotta give...

Longholder99 wrote: CancerSlayer I agree too that timeliness have a way of...

January 22, 2023

V.TLT

RE:RE:RE:RE:somethings gotta give...

Longholder99 wrote: Underpromise and overdeliver I think is more the case in...

January 22, 2023

V.TLT

RE:somethings gotta give...

Yajne wrote: I've gotta believe that TLT hasn't shown all of their...

January 22, 2023

V.TLT

RE:FDA stance

N0taP00p wrote: If you look up an article titled "FDA Is Speeding Up...

January 21, 2023

V.TLT

RE:RE:RE:RE:RE:RE:RE:Accelerated Approval ahead of AUA congress would spark

Eoganacht wrote: Hi Rumple - Roswell Park is already treating 3 types of skin...

January 20, 2023

V.TLT

RE:Preclinical Study: TLD-1433 vs Conjunctival Melanoma

Same abstract, but easier read.... Abstract The ruthenium-based...

January 19, 2023

V.TLT

Preclinical Study: TLD-1433 vs Conjunctival Melanoma

I'm unaware of PDT's clinical use against cutaneous/skin melanoma off...

January 19, 2023

V.TLT

RE:RE:Accelerated Approval ahead of AUA congress would spark

Eoganacht wrote: ScienceFirst wrote: "Accelerated Approval, instead of...

January 19, 2023

V.TLT

RE:FDA to rule on BLA for N-803 + BCG for NMIBC by May 23, 2023

Eoganacht wrote: If the FDA rules favourably for ImmunityBio's BLA in May...

January 15, 2023

V.TLT

RE:RE:Feature article about Theralase on biotuesdays.com website

  wildbird1 wrote: It does seem that this Jan 3,2023 article was...

January 15, 2023

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:Feature article about Theralase on biotuesdays.com website

Eoganacht wrote: There was a simulation study conducted by Drs. Wettstein...

January 9, 2023

V.TLT

RE:RE:RE:RE:RE:RE:Feature article about Theralase on biotuesdays.com website

CancerSlayer wrote:   A recent metanalysis in the journal of...

January 9, 2023

V.TLT

RE:RE:RE:RE:RE:Feature article about Theralase on biotuesdays.com website

  A recent metanalysis in the journal of European Urology Focus (3...

January 9, 2023

V.TLT

RE:RE:RE:RE:Feature article about Theralase on biotuesdays.com website

Eoganacht wrote: Our current trial is for high risk BCG unresponsive NMIBC...

January 9, 2023

V.TLT

RE:RE:Feature article about Theralase on biotuesdays.com website

Wildbird1 wrote: "Let's recap very briefly... 1) Merck BCG...

January 8, 2023

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:January 9th warrants

toade1313 wrote: And whenever someone asks why with all the things going for...

January 6, 2023

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:January 9th warrants

plantrader wrote: @N0taP00p, As we discussed before the disclaimer (excuse...

January 6, 2023